Timing of Toxicities and Mortality Following CAR T Therapy in Myeloma

Al-Ola A Abdallah, Plasma Cell Disorder Program Director, Division of HMCT/University of Kansas Medical Center, shared a post on X:

“Timing of Toxicities and Non-Relapse Mortality Following Chimeric antigen receptor (CAR) T Therapy in Myeloma by the Nausheen Ahmed, KU Cancer Center.

Things to Know:

• New-onset Cytokine Release Syndrome (CRS)/Immune effector Cell–Associated Neurotoxicity Syndrome (ICANS) are rare after 2 weeks from Idecabtagene Vicleucel
  and Ciltacabtagene Autoleucel infusion.
• Early Non Relapse Mortality (NRM), <30 days is driven by Immune Effector Cell-associated HLH-like Syndrome (IEC-HS) and infection.
• Late NRM (30-90 days) is driven by infection.
• Flexible Risk Evaluation and Mitigation Strategy (REMS) monitoring period partnering with local oncologists may be safe.”

Source: Al-Ola A Abdallah/X